INCLISIRAN - A NEW SOLUTION FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

Paulina Lis; Anna Lis; Wojciech Kaźmierski; Jakub Jurek; Mateusz Ziomek; Kinga Kocur; Anna Ziobro; Katarzyna Camlet

doi:10.56782/pps.241

Published : 2024-08-27

Vol. 22 No. 3 (2024)

Inclisiran - a new solution for the prevention and treatment of atherosclerotic cardiovascular disease

Paulina Lis

Anna Lis

Wojciech Kaźmierski

Jakub Jurek

Mateusz Ziomek

Kinga Kocur

Anna Ziobro

Katarzyna Camlet

DOI: https://doi.org/10.56782/pps.241

Abstract

A major cause of morbidity and mortality worldwide is atherosclerotic cardiovascular disease (ASCVD), the prevalence of which has been increasing significantly over the past few decades. Elevated concentration of low-density lipoprotein cholesterol (LDL-C) is one of the most important modifiable risk factors associated with the development of ASCVD. Lowering LDL-C concentration is an important intervention in the primary and secondary prevention of cardiovascular events in patients with ASCVD or at risk for ASCVD. Inclisiran is a new formulation containing small interfering RNA (siRNA) that inhibits the production of PCSK9 protein in the liver. Decreased production of PCSK 9 leads to lower LDL-C concentrations by increasing the formation of receptors that are responsible for LDL-C uptake, resulting in increased LDL-C uptake and consequently lower blood LDL-C concentrations. This narrative review discusses the effects of inclisiran on LDL-C concentrations, with the aim of evaluating the drug's efficacy, safety and tolerable doses. Studies confirm that inclisiran is an effective and safe LDL-C-lowering drug that reduces the risk of ASCVD. Inclisiran is another treatment in the standards for LDL-C-lowering therapy in patients with ASCVD or high risk of ASCVD.

Keywords:

inclisiran, atherosclerotic cardiovascular disease, PCSK9, cardiology

Similar Articles

Paulina Dąbrowska, Michał Żuber, Michał Dacka, Efficacy and safety of bempedoic acid in lipid disorder therapy: a review of clinical trials , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Maciej Bara, Jakub Starownik, Jakub Szydło, Patryk Gryszkiewicz, Jakub Nieznański, Dapagliflozin - new solution in chronic kidney disease treatment , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Jakub Olszewski, Katarzyn Kozon, Andrzej Patyra, Flozins in heart failure – a new reimbursement indication , Prospects in Pharmaceutical Sciences: Vol. 20 No. 1 (2022)
Natalia Korytowska, Beata Pytlak, Mariusz Niemczyk, CHRONIC KIDNEY DISEASE AND SELECTED ASPECTS OF KIDNEY RECIPIENTS MONITORING , Prospects in Pharmaceutical Sciences: Vol. 18 No. 4 (2020)
Maria Rybicka, Anna Seroka, Michał Obrębski, Justyna Chwiejczak, Aleksander Górny, Jan Kościan, Julita Młynarska, Karolina Szczerkowska, Anna Wójcik, Maria Mitkowska, Lipoprotein(a) - gaining clinical importance as a cardiovascular risk factor. Current state of medical knowledge. , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Mateusz Sobczyk, Daria Żuraw, Paulina Oleksa, Kacper Jasiński, Mikołaj Porzak, Michał Dacka, SGLT2 inhibitors and their possible use in prevention and treatment of neurological diseases , Prospects in Pharmaceutical Sciences: Vol. 22 No. 1 (2024)
Tomasz Kordowski, Tomasz Tatara, Adam Fronczak, REVIEW OF CURRENT GUIDELINES AND STUDIES ON USE OF ACETYLSALICYLIC ACID IN THE PRIMARY CARDIOVASCULAR EVENTS PREVENTION , Prospects in Pharmaceutical Sciences: Vol. 17 No. 4 (2019)
Katarzyna Łysiak, Anna Łysiak, The role of the gut microbiome in Alzheimer's disease , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Dominika Łacheta, Wioletta Olejarz, OCHRONNA ROLA KWASU α-LIPONOWEGO W MIAŻDŻYCY I CHOROBACH SERCOWO-NACZYNIOWYCH , Prospects in Pharmaceutical Sciences: Vol. 17 No. 8 (2019)
Adam Piasecki, Magdalena Sitnik, Jakub Olszewski, Maciej Bara, Katarzyna Herjan, Piotr Armański, The changing landscape of mineralocorticoid receptor antagonists – finerenone in cardiovascular and renal health , Prospects in Pharmaceutical Sciences: Vol. 22 No. 1 (2024)

1 2 3 4 5 6 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Lis, P., Lis, A., Kaźmierski, W., Jurek, J., Ziomek, M., Kocur, K., … Camlet, K. (2024). Inclisiran - a new solution for the prevention and treatment of atherosclerotic cardiovascular disease. Prospects in Pharmaceutical Sciences, 22(3), 136–141. https://doi.org/10.56782/pps.241

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Katsiki, N.; Vrablik, M.; Banach, M.; Gouni-Berthold, I. Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a). Pharmaceuticals, 2023, 16(4), Art. No: 577. doi: 10.3390/ph16040577 DOI: https://doi.org/10.3390/ph16040577

Grundy, S.M.; Stone, N.J; Bailey, A.L.; Beam, C.; Birtcher K.K.; Blumenthal, R.S.; Braun, L.T.; De Feranti S.; Faiella-Tommasino, J.; Forman, D.E.; Goldberg, R.; Heidenreich, P.A.; Hlatky, M.A.; Jones, D.W.; Lloyd-Jones, D.; Lopez-Pajares, N.; Ndumele, C.E.; Orringer, A.E.; Peralta, C.A.; Saseen, J.J.; Smith Jr, S.C.; Sperling, L.; Virani, S.S.; Yeboah, J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2018, 139(25), e1082–e1143. doi: 10.1161/CIR.0000000000000625 DOI: https://doi.org/10.1161/CIR.0000000000000624

Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; Backer, G.G.D.; Delgado, V.; Ference,B.A.; Graham, I.M.; Halliday, A.; Landmesser, U.; Mihaylova, B.; Pedersen, T.R.’ Riccardi, G.; Richter, D.J.; Sabatine, M.S.; Taskinen, M-R., Tokgozoglu, L.; Wiklund, O. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J., 2019, 41(1), 111-188. doi: 10.1093/eurheartj/ehz455 DOI: https://doi.org/10.15829/1560-4071-2020-3826

Karagiannis, An.D.; Mehta, A.; Dhindsa, D.S; Virani, S.S.; Orringer, C.E.; Blumenthal, R.S.; Stone, N.J.; Sperling, L.S. How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. Eur. Heart J., 2021, 42(22), 2154-2169. doi: 10.1093/eurheartj/ehaa1080 DOI: https://doi.org/10.1093/eurheartj/ehaa1080

Soffer, D.; Stoekenbroek, R.; Plakogiannis, R. Small interfering ribonucleic acid for cholesterol lowering - inclisiran: inclisiran for cholesterol lowering. J. Clin. Lipidol., 2022, 16, 574–582. doi:10.1016/j.jacl.2022.06.009 DOI: https://doi.org/10.1016/j.jacl.2022.06.009

Goldstein, J.L.; Brown, M.S. A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins. Cell, 2015, 161(1), 161-172. doi: 10.1016/j.cell.2015.01.036 DOI: https://doi.org/10.1016/j.cell.2015.01.036

Song, P.; Fang, Z.; Wang, H.; Cai, Y.; Rahimi, K.; Zhu, Y.; Fowkes, G.R.; Fowkes, F.J.; Rudan, I. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. The Lancet Glob. Health, 2020, 8(5), E721-E729. doi: 10.1016/S2214-109X(20)30117-0 DOI: https://doi.org/10.1016/S2214-109X(20)30117-0

Sopic, M.; Vilne, B.; Gerdts, E.; Trindade, F.; Uchida, S.; Khatib, S.; Wettinger, S.B.; Devaux, Y.; Magni, P. Multiomics tools for improved atherosclerotic cardiovascular disease management. Trends Mol. Med., 2023, 29(12), 983-995. doi: 10.1016/j.molmed.2023.09.004 DOI: https://doi.org/10.1016/j.molmed.2023.09.004

Patriki, D.; Saravi, S.S.S.; Camici, G.G.; Liberale, L.; Beer, J.H. PCSK 9: A Link Between Inflammation and Atherosclerosis. Curr. Med. Chem., 2021, 29(2), 251-267. doi: 10.2174/0929867328666210707192625 DOI: https://doi.org/10.2174/0929867328666210707192625

Nishikido, T. Clinical potencial of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease. Cardiovasc. Diabetol., 2023, 22, Art. No: 20. doi: 10.1186/s12933-023-01752-4 DOI: https://doi.org/10.1186/s12933-023-01752-4

Kallend, D.; Stoekenbroek, R.; He, Y.L.; Smith, P.F.; Wijngaard, P. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. J. Clin. Lipidol., 2022, 16(2), 208-219. doi: 10.1016/j.jacl.2022.01.001 DOI: https://doi.org/10.1016/j.jacl.2022.01.001

Wright, R.S.; Collins, M.G.; Stoekenbroek, R.M.; Robson, R.; Wijngaard, P.L.J.; Landmesser, U.; Leiter, L.A.; Kastelein, J.J.P.; Ray, K.K.; Kallend, D. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clin. Proc., 2020, 95(1), 77-89. doi: 10.1016/j.mayocp.2019.08.021 DOI: https://doi.org/10.1016/j.mayocp.2019.08.021

Leiter, L.A.; Teoh, H.; Kallend, D.; Wright, S.; Landmesser, U.; Wijngaard, P.L.J.; Kastelein, J.J.P.; Ray, K.K. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. Diabetes Care, 2019, 42(1), 173–176. doi: 10.2337/dc18-1491 DOI: https://doi.org/10.2337/dc18-1491

Ray, K.K.; Troguay, R.P.T.; Visseren, F.L.J.; Leiter, L.A.; Wright, S.; Vikarunnessa, S.; Talloczy, Z.; Zang, X.; Maheux, P.; Lesogor, A.; Landmesser, U. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol., 2023, 11(2), 109-119. doi: 10.1016/ S2213-8587(22)00353-9 DOI: https://doi.org/10.1016/S2213-8587(22)00353-9

Hovingh, G.K.; Lepor, N.E.; Kallend, D.; Stoekenbroek, R.M.; Wijngaard, P.; Raal, F.J. Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study. Circulation, 2020, 141(22), 1829-1831. doi: 10.1161/CIRCULATIONAHA.119.044431 DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.044431

Raal, F.; Durst, R.; Bi, R.; Talloczy, Z.; Maheux, P.; Lesogor, A.; Kastelein, J.J.P. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. Circulation, 2024, 149(5), 354-362. doi: 10.1161/CIRCULATIONAHA.122.063460 DOI: https://doi.org/10.1161/CIRCULATIONAHA.122.063460

Raal, F.; Kallend, D.; Ray, K.K.; Turner, T.; Koenig, W.; Wright, S.; Wijngaard, P.; Curcio, D.; Jaros, M.J.; Leiter, L.A.; Kastelein, J.J.P. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N. Engl. J. Med., 2020, 382(16), 1520-1530. doi: 10.1056/NEJMoa1913805 DOI: https://doi.org/10.1056/NEJMoa1913805

Ray, K.K.; Phil, M.; Wright, S.; Kallend, D.; Koenig, W.; Leiter, L.A.; Raal, F.J.; Bisch, J.A.; Richardson, T.; Jaros, M.; Wijngaard, P.; Kastelein, J.J.P. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N. Engl. J. Med., 2020, 382(16), 1507-1519. doi: 10.1056/NEJMoa1912387 DOI: https://doi.org/10.1056/NEJMoa1912387

Wright, S.; Ray, K.K.; Raal, F.J.; Kallend, D.G.; Jaros, M.; Koenig, W.; Leiter, L.A.; Landmesser, U.; Schwartz, G.G.; Friedman, A. Wijngaard, P.; Garcia Conde, L.; Kastelein, J.J.P. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J. Am. Coll. Cardiol., 2021, 77(9), 1182-1193. doi: 10.1016/j.jacc.2020.12.058 DOI: https://doi.org/10.1016/j.jacc.2020.12.058

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C (ORION-8). Available online: https://clinicaltrials.gov/study/NCT03814187 (accessed on 25.06.2024).

HPS-4 TIMI 65 ORION-4. Available online: https://www.orion4trial.org/homepage-uk (accessed on 26.06.2024).

Obwieszczenie Ministra Zdrowia z dnia 20 października 2022 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 listopada 2022 r. Available online: https://www.gov.pl/web/zdrowie/obwieszczenie-ministra-zdrowia-z-dnia--20-pazdziernika-2022-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych-na-1-listopada-2022-r. (accessed on 27.06.2024).

Paulina Lis

lispaulinab@gmail.com
https://orcid.org/0009-0004-0652-4822

Affiliation:

a:1:{s:5:"en_US";s:137:"Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach, Ziołowa 45/47, 40-635 Katowice";} Poland

Anna Lis

Affiliation:

Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach, Ziołowa 45/47, 40-635 Katowice Poland

Wojciech Kaźmierski

Affiliation:

Wydział Lekarski i Nauk o Zdrowiu, Akademia im. Andrzeja Frycza Modrzewskiego w Krakowie, Gustawa Herlinga-Grudzińskiego 1, 30-705 Kraków Poland

Jakub Jurek

Affiliation:

Wydział Lekarski i Nauk o Zdrowiu, Akademia im. Andrzeja Frycza Modrzewskiego w Krakowie, Gustawa Herlinga-Grudzińskiego 1, 30-705 Kraków Poland

Mateusz Ziomek

Affiliation:

Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy, Szaserów 128, 04-141 Warszawa Poland

Kinga Kocur

Affiliation:

Szpital Powiatowy im. Św. Maksymiliana w Oświęcimiu, Wysokie Brzegi 4, 32-600 Oświęcim Poland

Anna Ziobro

Affiliation:

Szpital Powiatowy im. dra Tytusa Chałubińskiego w Zakopanem, Kamieniec 10, 34-500 Zakopane Poland

Katarzyna Camlet

Affiliation:

Szpital Powiatowy im. dra Tytusa Chałubińskiego w Zakopanem, Kamieniec 10, 34-500 Zakopane Poland

Inclisiran - a new solution for the prevention and treatment of atherosclerotic cardiovascular disease

Paulina Lis

Anna Lis

Wojciech Kaźmierski

Jakub Jurek

Mateusz Ziomek

Kinga Kocur

Anna Ziobro

Katarzyna Camlet

Abstract

Keywords:

Most read articles by the same author(s)

Similar Articles

Paulina Lis

Anna Lis

Wojciech Kaźmierski

Jakub Jurek

Mateusz Ziomek

Kinga Kocur

Anna Ziobro

Katarzyna Camlet